Literature DB >> 6240447

Reversal of cardiac hypertrophy in humans.

R C Tarazi, F M Fouad.   

Abstract

Reversal of left ventricular (LV) hypertrophy has definitely been proved to follow effective blood pressure control in hypertensive patients. This reduction in cardiac mass does not depend solely on blood pressure levels as measured in routine follow-up; it varies markedly with the type of drug used and even among patients treated with the same antihypertensive agent. The factors influencing the degree of regression of hypertrophy include stability of blood pressure control (entailing diurnal variations and response to stress), neurohumoral disturbances or fluid retention induced by the antihypertensive drug, and the presence of associated cardiac disease, as well as individual variations such as genetic background and possibly age. LV performance at rest was not depressed by the reduction in cardiac mass but remained normal in relation to changes in LV end-systolic stress.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6240447     DOI: 10.1161/01.hyp.6.6_pt_2.iii140

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  Regression of left ventricular hypertrophy in "previously untreated" hypertensive blacks after 6 months of blood pressure reduction with alpha- and beta-adrenergic blockade and thiazide therapy.

Authors:  E Foster; J F Plehn; S A Bernard; N J Battinelli; M Huntington-Coats; C S Apstein
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 2.  Regression of increased left ventricular mass by antihypertensives.

Authors:  C J Lavie; H O Ventura; F H Messerli
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Ventricular performance in spontaneously hypertensive rats (SHR) with reduced cardiac mass.

Authors:  T Natsume; M B Kardon; B L Pegram; E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  Comparison between the effects of urapidil and methyldopa on left ventricular hypertrophy and haemodynamics in humans.

Authors:  C A Feldstein; A O Olivieri; R P Sabarís
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study.

Authors:  H G Kirpizidis; G S Papazachariou
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

6.  Regression of left ventricular hypertrophy on long-term treatment with captopril of severe hypertensives refractory to standard triple treatment.

Authors:  U de Faire; K Lindvall; G Andersson; S Eriksson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients.

Authors:  G P Vyssoulis; E A Karpanou; C E Pitsavos; T K Kourtis; A A Paleologos; P K Toutouzas
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

8.  Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension.

Authors:  K Okumura; J Kondo; M Yoshino; K Ishikawa; H Asano; H Hashimoto; T Ito
Journal:  Mol Cell Biochem       Date:  1992-05-13       Impact factor: 3.396

Review 9.  The 'athletic heart syndrome'. A critical review.

Authors:  K P George; L A Wolfe; G W Burggraf
Journal:  Sports Med       Date:  1991-05       Impact factor: 11.136

10.  Inhibition of angiotensin II and platelet-derived growth factor-induced vascular smooth muscle cell proliferation by calcium entry blockers.

Authors:  Y D Ko; A Sachinidis; G H Graack; M Appenheimer; A J Wieczorek; R Düsing; H Vetter
Journal:  Clin Investig       Date:  1992-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.